Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases
- PMID: 2858129
- DOI: 10.1126/science.2858129
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases
Abstract
Brain sections from patients who had died with senile dementia of the Alzheimer's type (SDAT), Huntington's disease (HD), or no neurologic disease were studied by autoradiography to measure sodium-independent L-[3H]glutamate binding. In brain sections from SDAT patients, glutamate binding was normal in the caudate, putamen, and claustrum but was lower than normal in the cortex. The decreased cortical binding represented a reduction in numbers of binding sites, not a change in binding affinity, and appeared to be the result of a specific decrease in numbers of the low-affinity quisqualate binding site. No significant changes in cortical binding of other ligands were observed. In brains from Huntington's disease patients, glutamate binding was lower in the caudate and putamen than in the same regions of brains from control and SDAT patients but was normal in the cortex. It is possible that development of positron-emitting probes for glutamate receptors may permit diagnosis of SDAT in vivo by means of positron emission tomographic scanning.
Similar articles
-
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.Proc Natl Acad Sci U S A. 1990 Feb;87(4):1352-6. doi: 10.1073/pnas.87.4.1352. Proc Natl Acad Sci U S A. 1990. PMID: 2154742 Free PMC article.
-
Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease.Neurosci Lett. 1986 Jun 18;67(2):198-202. doi: 10.1016/0304-3940(86)90397-6. Neurosci Lett. 1986. PMID: 2873534
-
Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex.Neurosci Lett. 1990 May 18;113(1):95-100. doi: 10.1016/0304-3940(90)90501-y. Neurosci Lett. 1990. PMID: 1973277
-
Abnormalities in glutamatergic mechanisms in human Huntington's disease.Ann Acad Med Singap. 1985 Jan;14(1):147-52. Ann Acad Med Singap. 1985. PMID: 2988404 Review.
-
Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?FASEB J. 1990 Jul;4(10):2745-52. doi: 10.1096/fasebj.4.10.2165009. FASEB J. 1990. PMID: 2165009 Review.
Cited by
-
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.Int J Mol Sci. 2020 Mar 31;21(7):2431. doi: 10.3390/ijms21072431. Int J Mol Sci. 2020. PMID: 32244523 Free PMC article.
-
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.Future Med Chem. 2012 Sep;4(13):1689-700. doi: 10.4155/fmc.12.122. Future Med Chem. 2012. PMID: 22924507 Free PMC article.
-
Hippocampal plasticity during the progression of Alzheimer's disease.Neuroscience. 2015 Nov 19;309:51-67. doi: 10.1016/j.neuroscience.2015.03.006. Epub 2015 Mar 12. Neuroscience. 2015. PMID: 25772787 Free PMC article. Review.
-
Asiatic acid, a pentacyclic triterpene in Centella asiatica, attenuates glutamate-induced cognitive deficits in mice and apoptosis in SH-SY5Y cells.Acta Pharmacol Sin. 2012 May;33(5):578-87. doi: 10.1038/aps.2012.3. Epub 2012 Mar 26. Acta Pharmacol Sin. 2012. PMID: 22447225 Free PMC article.
-
A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug.Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):157-63. doi: 10.1007/BF00178715. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8857592
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical